

ABSTRACT FORM ECAT SYMPOSIUM 8 – 9 NOVEMBER 2018

Name:

Stefan Tiefenbacher

Colorado Coagulation, Laboratory Corporation of America Holdings, Englewood, CO, United States

Title:

Haemophilia treatment and laboratory testing

Abstract:

This presentation will provide an overview of the novel Haemophilia A and B therapies (currently in development or recently approved) and review some of the challenges clinical laboratories may encounter when trying to measure the effectiveness of these treatments using standard coagulation assays commonly used in the clinical laboratory. Examples of observed assay differences for particular therapies and associated challenges that may be encountered by the clinical laboratory will be presented. The novel haemophilia treatments reviewed will include extended half-life (EHL) FVIII and FIX replacement therapies, FVIII and FIX gene therapies as well as novel target therapies (e.g. ACE-910).